Blue Diamond Ventures Inc (BLDV)

[JPS02]

CannaTech 2017 - The Future of Medicine: Genetics Based Personalized Treatment - Dr. David Meiri

Published on Apr 19, 2017

Dr. David "Dedi" Meiri from the Cancer Research lab at the Technion in Israel (aka "Dedi's Lab") takes us through a fascinating presentation on the identification of the effects of different Cannabis extracts on the proliferation and cell death of various cancer cell lines (and classification) according to genetic profile.

1. I think this is a very interesting presentation that takes a few replays to understand because I am not a scientist or Doctor. However, notice Dr. Meiri is looking for a specific cannabinoid to combat the illness based on the research he started 2 years ago.

2. They are now able to take an extract and identify the cannabinoids and 20 different strains that can be prescribed to the patient. Dr. Mieri mentions that each strain is a different medicine. There is a specifity between what is in the cannabis and what is affecting the cells being treated.

3. 96 different treatments are being analyzed by Israeli researchers and it is very important that the right type of cannabis is used to combat different illnesses due to the different effectiveness of each strain of cannabinoids. There is at least 144 different cannabinoids .

4. They are noticing that there is variability in the effectiveness of different cannabis types grown in different greenhouses at different times.

Connections to BLDV

5. Notice at 5:50 in the June 1, 2017 interview how the BLDV CEO refers to grow operations being set up in Florida and how they are high tech. The CEO explains that in the MMJ industry they are more concerned with the exact complement of cannabinoids in the plant. Josh indicates it is more of a recipe relying on genetics and monitoring of controllable factors within controlled spaces.

BLDV's environmental control knowledge through their work with Zeno Controls and Verve Living Systems gave them the position to understand the total environment of the space. Josh indicates that in the MMJ industry, it is important to bring technology to different areas. Connect the dots!

BLDV has tried to highlight the significant and strategic benefits of importing Israeli technologies for North American application in the following subsequent PRs and interviews:

6. 9/26/17 PR - Blue Diamond Ventures Inc. launches Israeli Operation to Develop Standards: http://www.otcmarkets.com/ajax/showNewsReleaseDocumentById.pdf?id=27510

7. 10/19/17 PR - Blue Diamond Ventures Inc., Cannabis Clean Update: https://www.otcmarkets.com/ajax/showNewsReleaseDocumentById.pdf?id=27825

8. 12/5/17 PR - Blue Diamond Consulting LLC secures rights to Oricann® Cannabis Lighting:
https://www.otcmarkets.com/ajax/showNewsReleaseDocumentById.pdf?id=28580

9. 12/21/17 PR - BLDV Acquires 25% of Cann10 North America Holdings Ltd. :
https://globenewswire.com/news-release/2017/12/21/1269006/0/en/BLDV-Acquires-25-of-Cann10-North-America-Holdings-Ltd.html

10. 12/4/17 BLDV CEO Interview:

11. Jan ’18 update – BLDV CEO Interview:

- I think as pharmaceutical companies introduce different cannabis extracts and doctors start prescribing different MMJ targeted to treat specific illnesses, they will require reliable cultivators that can control grow and environmental factors to ensure the right cannabinoids are provided in the right MMJ strain as part of a secure and safe MMJ supply on a consistent basis.

- Hence, this is why I think BLDV's approach to partner with Israeli firms to secure multiple opportunities to bring Medical Cannabis products and technology to North America where AMS will implement the correct high tech cultivation methods as part of the integrated facility approach is timely and full of foresight of the future MMJ market. See further information provided in these two posts:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=132672130

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=132701804

- Although this YT clip is from last year's CannaTech, I find it fascinating at how far ahead Israel is in researching medical cannabis technologies and which cannabinoids are effective to fight diseases. I think this presentation gives some good context on the role that Cann10’s Israeli technologies can have in supporting BLDV's science based approach through the bridge that they can provide to the BioCannacuetical on the road to Biopharmaceutical cannaceutical as mentioned in the 4/9/18 PR:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140117417

- Note that Dr. David Meiri is a member of scientific committee for the CannX 2018 – The 3rd International Medical Cannabis Conference being organized by Cann10 in Tel Aviv on 14-16 October 2018: https://cannx.org/2018/about-cannx/committee#.Wty4CTGWzIU

Go BLDV!